Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation

Cancer

Volumn 119, Issue 16, 2013, Pages 3043-3051

  Kwak, Eunice L ^a   Shapiro, Geoffrey I ^b   Cohen, Seth M ^c   Becerra, Carlos R ^d   Lenz, Heinz Josef ^e   Cheng, Wen Fang ^f   Su, Wu Chou ^g   Robohn, Meghan ^h   Le Maulf, Florence ⁱ   Lobmeyer, Maximilian T ^j   Chand, Vikram K ^h   Iafrate, A John ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^h BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

ⁱ BOEHRINGER INGELHEIM   (France)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

afatinib; EGFR; EGFR activating mutations; epidermal growth factor receptor; ErbB Family Blocker; gene amplification; HER2; human epidermal growth factor receptor 2; solid tumors

Indexed keywords

AFATINIB; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; BACTEREMIA; BILIARY TRACT CANCER; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER SCREENING; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DERMATITIS; DERMATITIS ACNEIFORM; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EGFR GENE; EPISTAXIS; ESCHERICHIA COLI INFECTION; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEMALE GENITAL TRACT FISTULA; FISTULA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GENE TARGETING; GENETIC SCREENING; GYNECOLOGIC CANCER; HEMATURIA; HER2 GENE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAUSEA; OPEN STUDY; PARONYCHIA; PELVIS PAIN SYNDROME; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; POLYSOME; PRIORITY JOURNAL; PROTEIN FAMILY; PRURITUS; RHINORRHEA; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; STOMATITIS; THORAX PAIN; TREATMENT RESPONSE; URINARY TRACT INFECTION; UROGENITAL TRACT CANCER; WEIGHT REDUCTION;

EID: 84881477255     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28120     Document Type: Article

References (32)

1. Hynes NE, MacDonald G,. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009; 21: 177-184.
2. Citri A, Yarden Y,. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7: 505-516.
3. Weinstein IB, Joe AK,. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Natl Clin Pract Oncol. 2006; 3: 448-457.
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
5. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
7. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
8. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
9. Yang JC-H, Schuler MH, Yamamoto N, et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations [abstract]. J Clin Oncol. 2012; 30 (18 suppl). Abstract LBA7500.
10. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012; 13: 539-548.
11. Guillamo JS, de Bouard S, Valable S, et al. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res. 2009; 15: 3697-3704.
12. El-Sahwi K, Bellone S, Cocco E, et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer. 2010; 102: 134-143.
13. Ross JS, Fletcher JA,. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998; 3: 237-252.
14. Stern HM,. Improving treatment of HER2-positive cancers: opportunities and challenges [serial online]. Sci Transl Med. 2012; 4: 127rv122.
15. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008; 27: 4702-4711.
16. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB Family Blocker. J Pharmacol Exp Ther. 2012; 343: 342-350.
17. Solca F, Baum A, Krause M, et al. Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2, in models of head and neck cancer. Eur J Cancer. 2007; 5 (suppl): 326-327.
18. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
19. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
20. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011; 12: 1004-1012.
21. Eskens FA, Mom CH, Planting AS, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008; 98: 80-85.
22. Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012; 69: 1051-1061.
23. Wainberg ZA, Anghel A, Desai AJ, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 2010; 16: 1509-1519.
24. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010; 457: 299-307.
25. Pignochino Y, Sarotto I, Peraldo-Neia C, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas [serial online]. BMC Cancer. 2010; 10: 631.
26. Wang WP, Wang KN, Gao Q, Chen LQ,. Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction [serial online]. World J Surg Oncol. 2012; 10: 14.
27. Blehm KN, Spiess PE, Bondaruk JE, et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006; 12: 4671-4677.
28. Chaux A, Cohen JS, Schultz L, et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol. 2012; 43: 1590-1595.
29. Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010; 116: 15-20.
30. Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible ErbB1 (EGFR) and ErbB2 (HER2) kinase inhibitor BIBW 2992 in patients with advanced solid tumours. J Clin Oncol. 2010; 28: 3965-3972.
31. Yang C, Shih J, Su W, et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-Lung 2) [abstract]. J Clin Oncol. 2010; 28 (15 suppl). Abstract 7521.
32. De Greve J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012; 76: 123-127.